An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
Status:
Terminated
Trial end date:
2018-10-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of lanabecestat compared with
placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study
will test the hypothesis that lanabecestat is a disease-modifying treatment for participants
with early Alzheimer´s disease, defined as the continuum of participants with mild cognitive
impairment (MCI) due to Alzheimer´s disease and participants diagnosed with mild dementia of
the Alzheimer´s type, as measured by change from baseline on the 13-item Alzheimer's Disease
Assessment Scale - Cognitive Subscale (ADAS-Cog13) score at week 104 in each of the 2
lanabecestat treatment groups compared with placebo.